ICD-10 Coding for Acute Myeloblastic Leukemia(C92.0, C92.00, C92.00A)
Comprehensive guide on ICD-10 coding for acute myeloblastic leukemia, including documentation requirements and coding pitfalls.
Complete code families applicable to Acute Myeloblastic Leukemia
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| C92.00 | Acute myeloblastic leukemia not having achieved remission | Use when AML is diagnosed and has not achieved remission. |
|
| C92.01 | Acute myeloblastic leukemia, in remission | Use when AML is in documented remission. |
|
| C92.02 | Acute myeloblastic leukemia, in relapse | Use when AML has relapsed after a period of remission. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutAcute Myeloblastic Leukemia
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Acute Myeloblastic Leukemia.
Failure to document remission status
Impact
Clinical: Impacts treatment decisions and monitoring., Regulatory: Non-compliance with documentation standards., Financial: Potential for incorrect billing and reimbursement.
Mitigation
Ensure remission status is updated in each patient visit note., Use templates to guide documentation.
Using non-specific C92.0 code
Impact
Reimbursement: Incorrect DRG assignment leading to financial loss., Compliance: Non-compliance with coding specificity requirements., Data Quality: Inaccurate data for clinical and research purposes.
Mitigation
Ensure use of specific codes C92.00, C92.01, or C92.02.
Remission Status Coding
Impact
Incorrect coding of remission status can lead to audit findings.
Mitigation
Implement regular training on remission status documentation.